EichorEICHOR
Condition: Recurrent Non Hodgkin Lymphoma Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Recurrent Non Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Phase N/A · 8 location(s) · AIDS Malignancy Consortium · NCT05663502CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06550427Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-
Phase 1 · 20 location(s) · Regeneron Pharmaceuticals · NCT05685173Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT05436223Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
NA · 1 location(s) · Beijing GoBroad Hospital · NCT06618313Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07343934Phase Ib Clinical Study of Keynatinib
Phase 1 · 4 location(s) · Medolution Ltd. · NCT04807881A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07609030Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell
Phase 1/Phase 2 · 4 location(s) · City of Hope Medical Center · NCT03011814Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Phase 1 · 2 location(s) · ImmunityBio, Inc. · NCT05618925A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1 · 5 location(s) · Treeline Biosciences, Inc. · NCT06733441Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05098613CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2 · 94 location(s) · AstraZeneca · NCT06526793Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · 87 location(s) · National Cancer Institute (NCI) · NCT06649812A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap
Phase 1/Phase 2 · 50 location(s) · BeOne Medicines · NCT06634589A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · 82 location(s) · Pfizer · NCT03460977Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/Phase 2 · 2 location(s) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · NCT05768529Amping up With PemJAK
Phase 2 · 1 location(s) · Seda S. Tolu · NCT07283822Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.